Search Results - "Calleja, Alan"

Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis by Lane, Thirusha, Fontana, Marianna, Martinez-Naharro, Ana, Quarta, Candida Cristina, Whelan, Carol J, Petrie, Aviva, Rowczenio, Dorota M, Gilbertson, Janet A, Hutt, David F, Rezk, Tamer, Strehina, Svetla G, Caringal-Galima, Joan, Manwani, Richa, Sharpley, Faye A, Wechalekar, Ashutosh D, Lachmann, Helen J, Mahmood, Shameem, Sachchithanantham, Sajitha, Drage, Edmund P.S, Jenner, Harvey D, McDonald, Rosie, Bertolli, Ottavia, Calleja, Alan, Hawkins, Philip N, Gillmore, Julian D

“…BACKGROUND:Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure in older individuals. We sought to…”
Get full text

Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis by Carroll, Robert, Bortolini, Margherita, Calleja, Alan, Munro, Robin, Kong, Shiying, Daumont, Melinda J, Penrod, John R, Lakhdari, Khalid, Lacoin, Laure, Cheung, Winson Y

“…As part of the multi-country I-O Optimise research initiative, this population-based study evaluated real-world treatment patterns and overall survival (OS) in…”
Get full text

Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018 by Wolf, Andrea, Stratmann, Jan A, Shaid, Shabnam, Niklas, Nicolas, Calleja, Alan, Ubhi, Harveen, Munro, Robin, Waldenberger, Daniela, Carroll, Robert, Daumont, Melinda J, Penrod, John R, Lacoin, Laure, Rohde, Gernot

“…Immune checkpoint inhibitors (ICIs) have improved outcomes for patients with advanced non-small cell lung cancer (NSCLC) versus chemotherapy in clinical…”
Get full text

Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013–2017: A nationwide CAS registry analysis from the I-O Optimise initiative by Baas, Paul, Daumont, Melinda J., Lacoin, Laure, Penrod, John R., Carroll, Robert, Venkatesan, Sudhir, Ubhi, Harveen, Calleja, Alan, Snee, Michael

“…•In England in 2013–2017, half of MPM patients received only best supportive care.•Around 5% of patients with MPM underwent surgery.•33% received…”
Get full text

Assessment of Biologic Treatment Outcomes in Inflammatory Bowel Disease Patients with ‘Early Diseaseʼ: Results of a Systematic Literature Review: 584 by Dulai, Parambir S., Jairath, Vipul, Wright, Donna, Calleja, Alan, Demuth, Dirk, Campbell-Hill, Sarah, Peyrin-Biroulet, Laurent

“…Introduction: Early disease control with biologic treatment (Tx) in patients (pts) with inflammatory bowel disease (IBD) may modify the disease course;…”
Get full text

Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany by Griesinger, Frank, Pérol, Maurice, Girard, Nicolas, Durand-Zaleski, Isabelle, Zacharias, Stefan, Bosquet, Lise, Jänicke, Martina, Quantin, Xavier, Groth, Annika, Fleitz, Annette, Calleja, Alan, Patel, Sonya, Lacoin, Laure, Daumont, Melinda J., Penrod, John R., Carroll, Robert, Waldenberger, Daniela, Reynaud, Dorothée, Thomas, Michael, Chouaid, Christos

“…•Treatments and outcomes in locally advanced/metastatic non-small cell lung cancer.•Real-world patients in France and Germany (2015–2018) without ALK/EGFR…”
Get full text

Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts by Chouaid, Christos, Thomas, Michael, Debieuvre, Didier, Durand-Zaleski, Isabelle, Zacharias, Stefan, Bosquet, Lise, Groth, Annika, Fleitz, Annette, Calleja, Alan, Patel, Sonya, Lacoin, Laure, Daumont, Melinda J, Penrod, John R, Carroll, Robert, Waldenberger, Daniela, Cotté, François-Emery, Audigier-Valette, Clarisse, Griesinger, Frank

“…This study reports characteristics and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (aNSCLC) receiving nivolumab in…”
Get full text

Bridging the Gap Between RCTs and RWE Through Endpoint Selection by LoCasale, Robert J, Pashos, Chris L, Gutierrez, Ben, Dreyer, Nancy A, Collins, Toby, Calleja, Alan, Seewald, Michael J, Plumb, Jonathan M, Liwing, Johan, Tepie, Maurille Feudjo, Khosla, Sajan

“…This commentary is authored by several industry real-world evidence (RWE) experts, with support from IQVIA, as part of the 'RWE Leadership Forum': a group of…”
Get more information